Regulatory Science: Perspectives – part of the Kantoff-Sang Lecture Series – registration deadline extended to October 19, 2012

In a recent publication from the Institute of Medicine (IOM) entitled, “Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development”, the Food and Drug Administration (FDA) defines regulatory science as the “science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.” This symposium will include presentations by four of the leaders in the field of regulatory science:

Janet Woodcock, M.D. (FDA, Center for Drug Evaluation and Research)
Michael Rosenblatt, M.D. (Merck)
Elliott Antman, M.D. (Brigham and Women’s Hospital)
William Fisher, III, J.D., Ph.D. (Harvard Law School)

Following presentations, the audience will be invited to explore these topics further during an hour-long panel, moderated by Joshua Boger, Ph.D. The presentations and panel discussion will be followed by a reception to foster continued discussion. Members of the academic and pharmaceutical industries are welcome to attend.

Monday, October 29, 2012
4:00 PM – 7:00 PM
Merck Auditorium and Atrium (1st floor)
33 Avenue Louis Pasteur
Boston, MA 02115

Space is limited. Please apply here by October 19, 2012.

Please E-mail us with any questions.